A practical nomogram based on serum interleukin-6 for the prognosis of liver failure

Background Liver failure (LF) is a serious liver function damage caused by various factors, mainly jaundice, hepatic encephalopathy, coagulation disorders and multiple organ failure, with the clinical characteristic of high short-term mortality. LF is often accompanied by excessive activation of inflammatory factors, and an excessive systemic inflammatory response (i.e., inflammatory storm) is considered to be the trigger of LF. However, a specific prognostic model including inflammatory factors for patients with LF has not been well established. Aim To establish and validate a nomogram for predicting 28-day, 90-day, and 180-day mortality in patients with LF. Methods A total of 423 eligible LF patients were enrolled in this retrospective study. Independent predictors were identified using a multivariate logistic model and then integrated into a nomogram to predict 28-day, 90-day, and 180-day mortality. The concordance index, receiver operating characteristic curves, and calibration plots were used to evaluate the performance of the model. Results Sex, age, total bilirubin, aspartate aminotransferase, international normalized ratio, Child–Pugh score, and serum interleukin-6 were independent risk factors for death at 28, 90, and 180 days in LF patients. The nomogram showed good calibration and discrimination with an area under the receiver operating characteristic curve (AUC) of 0.927. The calibration curve fit as well, indicating that the nomogram had good clinical application value. Conclusion This nomogram model for predicting the 28-day, 90-day, and 180-day mortality of LF patients could help optimize treatment strategies and improve prognosis.

[1]  zhi-liang gao,et al.  Plasma Interleukin-6 Level: A Potential Prognostic Indicator of Emergent HBV-Associated ACLF , 2021, Canadian journal of gastroenterology & hepatology.

[2]  W. Kim,et al.  Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases , 2021 .

[3]  J. Lai,et al.  Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases , 2021, Hepatology.

[4]  G. D’Amico,et al.  TOWARDS A NEW DEFINITION OF DECOMPENSATED CIRRHOSIS. , 2021, Journal of hepatology.

[5]  W. Kim,et al.  Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases , 2021, Hepatology.

[6]  Meng Zheng,et al.  UMSCs Attenuate LPS/D-GalN-induced Acute Liver Failure in Mice by Down-regulating the MyD88/NF-κB Pathway , 2021, Journal of clinical and translational hepatology.

[7]  Roshan George,et al.  Cystatin C and interleukin‐6 for prognosticating patients with acute decompensation of cirrhosis , 2021, JGH Open.

[8]  J. Clària,et al.  Leukocytes, Systemic Inflammation and Immunopathology in Acute-on-Chronic Liver Failure , 2020, Cells.

[9]  Ning Zhang,et al.  High levels of serum interleukin-6 increase mortality of hepatitis B virus-associated acute-on-chronic liver failure , 2020, World journal of gastroenterology.

[10]  P. Galle,et al.  Raised serum Interleukin‐6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy , 2019, Alimentary pharmacology & therapeutics.

[11]  William M. Lee,et al.  Acute liver failure , 2019, The Lancet.

[12]  A. de Gottardi,et al.  Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis , 2019, Front. Immunol..

[13]  Liver Failure Guideline for diagnosis and treatment of liver failure , 2019 .

[14]  Failure Guideline for diagnosis and treatment of liver failure , 2018 .

[15]  R. Moreau,et al.  Cell death markers in patients with cirrhosis and acute decompensation , 2017, Hepatology.

[16]  D. Harats,et al.  Interleukin-1α and Interleukin-1β play a central role in the pathogenesis of fulminant hepatic failure in mice , 2017, PloS one.

[17]  Jun Yu Li,et al.  Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure , 2017, Gut.

[18]  T. Berg,et al.  Increased Level of Interleukin 6 Associates With Increased 90‐Day and 1‐Year Mortality in Patients With End‐Stage Liver Disease , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  M. Bazzo,et al.  From stable disease to acute‐on‐chronic liver failure: Circulating cytokines are related to prognosis in different stages of cirrhosis , 2017, Cytokine.

[20]  Richard Moreau,et al.  Systemic inflammation in decompensated cirrhosis: Characterization and role in acute‐on‐chronic liver failure , 2016, Hepatology.

[21]  Ashok Choudhury,et al.  Acute-on-chronic liver failure: terminology, mechanisms and management , 2016, Nature Reviews Gastroenterology &Hepatology.

[22]  Lei Qu,et al.  The Relationship Between Serum Interleukin-6 and the Recurrence of Hepatitis B Virus Related Hepatocellular Carcinoma after Curative Resection , 2015, Medicine.

[23]  Y. Li,et al.  Comparison of Current Diagnostic Criteria for Acute-On-Chronic Liver Failure , 2015, PloS one.

[24]  W. Kim,et al.  Toward an improved definition of acute-on-chronic liver failure. , 2014, Gastroenterology.

[25]  E. Christensen,et al.  Cardiac and proinflammatory markers predict prognosis in cirrhosis , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[26]  Uma Maheshwari,et al.  Early indicators of prognosis in fulminant hepatic failure: An assessment of the Model for End‐Stage Liver Disease (MELD) and King's College Hospital Criteria , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[27]  L. Fainboim,et al.  Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severity. , 2016, Cytokine.